Ovarian cancer biotech Cynvec inches forward in $10 million round
New York-based biotech company, Cynvec, is currently raising capital to aid in the development of a vaccine designed to treat ovarian cancer.
New York-based biotech company, Cynvec, is currently raising capital to aid in the development of a vaccine designed to treat ovarian cancer.